Bayer's Q1 Profit Surge Obscured by €2 Billion Legal Outflow and $7.25B Settlement Cliff

Bayer posts strong Q1 earnings beat, but €2.3B litigation cash drain and June 4 Roundup opt-out deadline keep stock under pressure. Progress on asundexian pharma pipeline offers hope.

Bayer delivered a surprisingly strong first-quarter earnings beat, but the numbers tell only half the story. A looming opt-out deadline for its $7.25 billion Roundup settlement and a €2.3 billion quarterly cash drain from litigation payments are keeping the stock under pressure, even as the underlying business shows real momentum.

Revenue rose 4.1% on a currency- and portfolio-adjusted basis to €13.4 billion. Earnings before interest, tax, depreciation and amortisation, stripping out special items, jumped 9% to €4.5 billion. The adjusted operating result, which includes a different set of exclusions, climbed by the same rate to €4.45 billion — comfortably ahead of analyst forecasts. Core earnings per share advanced 12.9% to €2.71, while reported earnings came in at €2.81.

The crop science division was the standout performer. Although sales growth was moderate, the business was buoyed by lucrative soybean licensing revenues that padded margins. That helped offset a hefty net financial debt pile that stood at €32.5 billion at the end of March. Free cash flow swung to negative €2.3 billion, driven almost entirely by legal settlements — approximately €2 billion of that outflow related to PCB and glyphosate litigation.

All eyes are now on June 4, the deadline for potential plaintiffs to opt out of the proposed class-action settlement covering Roundup claims. A federal judge in St. Louis granted preliminary approval to the accord — worth up to $7.25 billion — in early March. If too many claimants choose to opt out, Bayer subsidiary Monsanto reserves the right to walk away from the deal without any payouts. Chief executive Bill Anderson has cautioned that clarity on the opt-out tally may not come until several weeks afterwards. The final approval hearing is set for July, at the same time that the U.S. Supreme Court is expected to deliver its own ruling on a separate glyphosate case — both decisions are anticipated by the end of next month.

Anderson sounded a cautiously optimistic note, pointing to an important backstop: even if the Supreme Court rules against Bayer, the company still expects to significantly contain its legal exposure this year. Provisions for glyphosate lawsuits have been raised to €9.6 billion, and Bayer has secured an $8 billion credit line to cover immediate funding needs.

Analysts remain divided on valuation. UBS rates Bayer a buy with a €52 price target, while Deutsche Bank Research keeps a hold rating and a fair value of €45, citing ongoing legal uncertainty. The stock’s price-to-sales ratio of roughly 0.8 sits well below the industry average — a discount that reflects the persistent litigation overhang.

Beyond the courtroom, Bayer is trying to build a strategic counterweight in its pharma pipeline. Its Factor XIa inhibitor asundexian demonstrated a 26% reduction in ischaemic strokes versus placebo in the Phase III OCEANIC-STROKE trial, with no elevated bleeding risk. The U.S. Food and Drug Administration has granted fast-track designation. Rivals Bristol-Myers Squibb and Johnson & Johnson are expected to release Phase III data for their competing molecule milvexian in the second half of 2026. Analysts estimate the addressable market at $3 billion to $4 billion.

The shares currently trade at around €38.36 — roughly 22% below the 52-week high hit in February. Year-to-date the stock is virtually flat, but over the past twelve months it has gained more than 71%, leaving the 200-day moving average well in the rear-view mirror. Management has confirmed full-year guidance calling for core earnings of at least €4.10 per share and currency-adjusted EBITDA between €9.6 billion and €10.1 billion — subject to the legal environment not worsening further.